Syndax Pharmaceuticals Inc (SNDX) concluded trading on Thursday at a closing price of $14.41, with 4.03 million shares of worth about $58.12 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.10% during that period and on January 23, 2025 the price saw a gain of about 2.93%. Currently the company’s common shares owned by public are about 85.57M shares, out of which, 81.08M shares are available for trading.
Stock saw a price change of 12.58% in past 5 days and over the past one month there was a price change of 12.14%. Year-to-date (YTD), SNDX shares are showing a performance of 9.00% which decreased to -30.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.06 but also hit the highest price of $25.34 during that period. The average intraday trading volume for Syndax Pharmaceuticals Inc shares is 2.17 million. The stock is currently trading 7.93% above its 20-day simple moving average (SMA20), while that difference is down -3.27% for SMA50 and it goes to -24.33% lower than SMA200.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) currently have 85.57M outstanding shares and institutions hold larger chunk of about 102.20% of that.
The stock has a current market capitalization of $1.23B and its 3Y-monthly beta is at 0.90. It has posted earnings per share of -$3.63 in the same period. It has Quick Ratio of 6.99 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SNDX, volatility over the week remained 5.05% while standing at 4.82% over the month.
Analysts are in expectations that Syndax Pharmaceuticals Inc (SNDX) stock would likely to be making an EPS of -0.25 in the current quarter, while forecast for next quarter EPS is -1.1 and it is -3.78 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.27 which is 3.49 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.0 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -16.86% while it is estimated to decrease by -10.67% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on October 24, 2024 offering a Buy rating for the stock and assigned a target price of $37 to it. Coverage by Jefferies stated Syndax Pharmaceuticals Inc (SNDX) stock as a Buy in their note to investors on June 28, 2024, suggesting a price target of $37 for the stock. On January 31, 2024, Scotiabank Downgrade their recommendations, while on December 22, 2023, Mizuho Initiated their ratings for the stock with a price target of $45. Stock get a Buy rating from BofA Securities on October 25, 2023.
